Trials / Completed
CompletedNCT05982314
Extension Safety and Immunogenicity Study of GPNV-001
A Safety and Immunogenicity Extension Study of GPNV-001
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- GPN Vaccines · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Accepted
Summary
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
Detailed description
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine. Up to 20 participants per cohort will be invited.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gamma-PN3 | Experimental whole-cell pneumococcal vaccine |
| BIOLOGICAL | Pneumovax-23 | Licensed pneumococcal vaccine |
| BIOLOGICAL | Prevenar-13 | Licensed pneumococcal vaccine |
| BIOLOGICAL | Placebo | Saline placebo |
Timeline
- Start date
- 2023-07-17
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2023-08-08
- Last updated
- 2024-12-18
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05982314. Inclusion in this directory is not an endorsement.